Cost-effectiveness analyses alongside randomised clinical trials
Background: Many health economists increasingly advocate the use of model-based evaluations rather than trial-based evaluations. Purpose: The purpose of this paper is to review the merits and limitations of RCT-based evaluations of cost-effectiveness. Results: The paper draws on the examples of larg...
| מחבר ראשי: | |
|---|---|
| פורמט: | Conference item |
| יצא לאור: |
2006
|
| _version_ | 1826301221911134208 |
|---|---|
| author | Gray, A |
| author_facet | Gray, A |
| author_sort | Gray, A |
| collection | OXFORD |
| description | Background: Many health economists increasingly advocate the use of model-based evaluations rather than trial-based evaluations. Purpose: The purpose of this paper is to review the merits and limitations of RCT-based evaluations of cost-effectiveness. Results: The paper draws on the examples of large studies such as the United Kingdom Prospective Diabetes Study and the Heart Protection Study to suggest that large randomised trials offer a number of advantages to health economists wishing to estimate cost-effectiveness, including access to patient-level data, unbiased estimates of resource use as well as effects, the estimation of cost-effectiveness in sub-groups of patients, and an enhanced ability to build and validate extrapolation models. Conclusions: While many methodological issues remain to be resolved, the use of patient-level data derived from clinical trials as a basis for economic evaluations is likely to remain an important part of the health economics evidence base, and will also continue to provide the data required for methodological research. © Society for Clinical Trials 2006. |
| first_indexed | 2024-03-07T05:29:07Z |
| format | Conference item |
| id | oxford-uuid:e197b51d-b4f7-498b-a1d3-50fc97e9bc51 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T05:29:07Z |
| publishDate | 2006 |
| record_format | dspace |
| spelling | oxford-uuid:e197b51d-b4f7-498b-a1d3-50fc97e9bc512022-03-27T09:55:32ZCost-effectiveness analyses alongside randomised clinical trialsConference itemhttp://purl.org/coar/resource_type/c_5794uuid:e197b51d-b4f7-498b-a1d3-50fc97e9bc51Symplectic Elements at Oxford2006Gray, ABackground: Many health economists increasingly advocate the use of model-based evaluations rather than trial-based evaluations. Purpose: The purpose of this paper is to review the merits and limitations of RCT-based evaluations of cost-effectiveness. Results: The paper draws on the examples of large studies such as the United Kingdom Prospective Diabetes Study and the Heart Protection Study to suggest that large randomised trials offer a number of advantages to health economists wishing to estimate cost-effectiveness, including access to patient-level data, unbiased estimates of resource use as well as effects, the estimation of cost-effectiveness in sub-groups of patients, and an enhanced ability to build and validate extrapolation models. Conclusions: While many methodological issues remain to be resolved, the use of patient-level data derived from clinical trials as a basis for economic evaluations is likely to remain an important part of the health economics evidence base, and will also continue to provide the data required for methodological research. © Society for Clinical Trials 2006. |
| spellingShingle | Gray, A Cost-effectiveness analyses alongside randomised clinical trials |
| title | Cost-effectiveness analyses alongside randomised clinical trials |
| title_full | Cost-effectiveness analyses alongside randomised clinical trials |
| title_fullStr | Cost-effectiveness analyses alongside randomised clinical trials |
| title_full_unstemmed | Cost-effectiveness analyses alongside randomised clinical trials |
| title_short | Cost-effectiveness analyses alongside randomised clinical trials |
| title_sort | cost effectiveness analyses alongside randomised clinical trials |
| work_keys_str_mv | AT graya costeffectivenessanalysesalongsiderandomisedclinicaltrials |